Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 1, 2025
Daily News
August 1, 2025
- Japan Panel OKs Taisho’s Insomnia Med, 2 Other NMEs for Approval
August 1, 2025
- Leqembi Maintains Benefits in Early Alzheimer’s after 4 Years of Treatment
August 1, 2025
- Kyowa Kirin Sees Flat H1 Revenue as Japan Slump Offsets Overseas Gains
August 1, 2025
- Otsuka Accelerates Pipeline Investment Centered on “Next 8” as Growth Drivers
August 1, 2025
- Sumitomo Pharma Rejoins PhRMA amid US Tariff Concerns, Posts H1 Forecasts
August 1, 2025
- Daiichi Sankyo Plays Down Tariff Impact for FY2025, Eyes US Production Boost
August 1, 2025
- Leqembi’s April-June Sales at 23.1 Billion Yen: Eisai
August 1, 2025
- Nihon Chouzai to Go Private through Tender Offer Backed by Advantage Partners
August 1, 2025
- MHLW Selects 20 Organizations to Bolster Drug Discovery Clusters
August 1, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…